UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of October 2006
Commission File Number 000-50994
BioProgress PLC
(Translation of registrant’s name into English)
15-17 Cambridge Science Park
Milton Road, Cambridge CB4 0FQ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):N/A
.
For Immediate Release 27 October 2006
BioProgress plc
Appointment of Non-Executive Director
London, UK, 27 October 2006: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharma and
healthcare company, is pleased to announce the appointment of Dr James Robert Murray as a Non-Executive Director of BioProgress.
Dr Murray, age 62, has 30 years' experience in the pharmaceutical industry including executive positions at Gist-Brocades NV and
Shire Pharmaceuticals Group plc, which he co-founded becoming Research Director in 1990. He was most recently Chief Executive Officer
of Hunter-Fleming Ltd, a bio-pharmaceutical company where he is now President.
Dr Murray is a member of Bristol University's Innovations Board and is an advisor to the University's Vice Chancellor. He is a
member of the Research and Industry Council of the South West Regional Development Agency.
Dr Murray is a member of the Board of Trustees of the Breast Cancer Campaign, London. He has degrees in Medicine and Surgery
(Charing Cross Hospital, London), is a Fellow of the Faculty of Pharmaceutical Medicine of the Joint Royal Colleges of Physicians,
holds Diplomas in Obstetrics and Family Planning and Reproductive Medicine of the Royal College of Obstetricians and Gynaecologists.
He is a Member of the Royal College of General Practitioners, the British Medical Association, the BioIndustry Association, the
American Academy of Pharmaceutical Physicians and the Institute of Directors. He is also a Fellow of the Royal Society of Medicine
and of the American Academy of Dermatology.
Richard Trevillion, Chief Executive Officer of BioProgress, said:
"I'm delighted to welcome Jim to our Board. Jim has unparalleled experience in product development which is becoming more of an
operational feature of the Company. He has been involved with the Company's Advisory Board since its formation. As the Company's
development and new product launch programme continues to expand, Jim's experience will be invaluable in the continued execution of
our strategy".
Dr James Murray said:
"I've worked with Richard and the team since the formation of the Advisory Board earlier this year. The changes within the business
since that time have been profound and I'm very pleased to be taking a more active role assisting in the continued growth and
development of the company which will draw on my experience over the past 30 years."
Dr Murray is currently a director of Hunter Fleming Limited. In the past five years he has held directorships with Hunter-Fleming
Ltd, Cutest Systems Ltd and ProXara Ltd and is a Trustee of the Breast Cancer Campaign. No further disclosures are required to be
made in relation to Dr.Murray under schedule 2 (g) of the AIM rules.
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer
and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in
application within 24 patent families and has product development agreements and strategic alliances with several global companies.
As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™
polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further
information please go to www.bioprogress.com
Forward-Looking Information.
The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this
announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The
forward-looking statements in this release include statements addressing future financial and operating results and the timing and
benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual
results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no
obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of
new information, future events or otherwise. This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of
securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to
inform themselves about and to observe such restrictions.
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.